Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Analysts are intrested in these 5 stocks: ( ($MRK) ), ( ($REGN) ), ( ($CLRB) ), ( ($HUMA) ) and ( ($FL) ). Here is a ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Applications are now open. The deadline to apply is May 16 at 4:29 p.m. The Starter Company Plus Grant supports eligible entrepreneurs looking to build their small businesses. Select entrepreneurs ...

The company’s Chief Scientific Officer, George D. Yancopoulos, M.D., Ph.D., expressed optimism about the potential of these treatments, including Libtayo, which is already a standard of care for ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

Libtayo in the U.S. grew 21% compared to the first quarter of last year and has established itself as a cornerstone therapy for advanced non-melanoma skin cancer, while its share of the lung ...

Persistent Systems Ltd got more revenue than Hexaware Technologies Ltd in the January-March 2025 period, making it the country’s ninth-largest information technology (IT) services company.

Oncology Programs The Company submitted an sBLA to the FDA and a regulatory application in the EU for Libtayo (cemiplimab) in adjuvant CSCC based upon data from a Phase 3 trial which demonstrated ...

The company also has an extremely full earlier ... Among oncology drugs, PD-1 antibody Libtayo is at the center, and is seeing solid growth (albeit from a smaller base) in niche indications ...